Genocea Biosciences (GNCA) Misses Q1 EPS by 6c

Genocea Biosciences (NASDAQ: GNCA) reported Q1 EPS of ($0.21), $0.06 worse than the analyst estimate of ($0.15).

“2018 has been an exciting year for Genocea,” said Chip Clark, president and chief executive officer of the company. “Following our January financing, we are funded to advance our lead neoantigen cancer vaccine candidate GEN-009 into clinical trials later this year, and to continue to generate and present scientific data further elaborating on the ability of our ATLAS platform to identify and characterize neoantigens for use in cancer vaccines.”

For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• SanDisk upgraded at JPMorgan after investor day; shares climb